KisoJi Biotechnology is at the forefront of next-generation antibody therapeutics, focusing on the discovery and development of highly differentiated antibodies to tackle challenging targets in oncology and other diseases. The company utilizes a proprietary antibody platform that allows for the visualization of the complete immune response in animals, providing direct control over antibody sampling. This platform is based on single domain antibodies derived from KisoJi's multi-species transgenic mice, combined with AI-enabled antibody fingerprinting technology. This innovative approach enables the creation of robust, easily manufacturable multi-specific antibodies, which are essential for therapeutic, diagnostic, and vaccine development.

One of KisoJi's lead assets is KJ-103, a naked anti-TROP2 antibody designed to activate the immune system without the need for a cytotoxic payload, distinguishing it from traditional antibody-drug conjugates. KJ-103 binds to a unique epitope on TROP2, facilitating the recruitment of immune cells to target and eliminate tumor cells. This novel mechanism of action aims to provide effective treatment options for various TROP2-expressing cancers, including colorectal, breast, and lung cancers, particularly in cases where existing therapies may be ineffective or too toxic. KisoJi's commitment to leveraging advanced scientific and AI tools positions it as a leader in the development of transformative antibody therapeutics.

Canada

KisoJi is dedicated to developing multi-specific antibody technologies and therapeutics that improve outcomes in oncology. 

KisoJi Biotechnology

Company Details